Rocket Pharmaceuticals (9IP1) AI Stock Analysis

2 Followers

Rocket Pharmaceuticals

(Frankfurt:9IP1)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Low leverage and equity supportRelatively low leverage compared with the equity base reduces immediate financial risk and preserves flexibility while Rocket advances its clinical pipeline. Although equity has declined, the balance sheet still provides a foundation for funding development and managing obligations over the next several quarters.

Negative Factors

No revenue and persistent lossesRocket remains pre-commercial, so its operating model currently depends on research spending without product revenue to offset costs. Persistent losses limit internal funding capacity and mean that meaningful improvement in financial performance remains dependent on successful clinical development and eventual commercialization.

Rocket Pharmaceuticals (9IP1) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 272.24M
Dividend Yield: ―
Average Volume (3M): 1,300
Price to Earnings (P/E): -15.5
Beta (1Y): 1.26
Revenue Growth: ―
EPS Growth: 94.06%
Country: Germany
Employees: 202
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Rocket Pharmaceuticals Business Overview & Revenue Model

Company Description

Rocket Pharmaceuticals, Inc., operating alongside its affiliates, is an innovative biotechnology enterprise dedicated to pioneering gene therapies for rare and severely debilitating diseases. The company's active clinical pipeline features multiple p...

Rocket Pharmaceuticals Risk Analysis

Rocket Pharmaceuticals disclosed 3 risk factors in its most recent earnings report. Rocket Pharmaceuticals reported the most risks in the "Legal & Regulatory" category.

Legal & Regulatory - Litigation, compliance, new legislation, and taxation risks

Latest Risks Added

2 New Risks

1.Our strategic restructuring may not result in the savings we anticipate, could result in total costs and expenses that are greater than expected and could disrupt our operationsQ2, 2025

2.We are and may continue to be targets of securities-related class action and derivative lawsuits and defending against these claims could result in substantial costs and divert management time and resources and have a material adverse effect on our results of operations. These lawsuits, and any other lawsuits to which we are subject, may be costly to defend or pursue and are uncertain in their outcomeQ2, 2025

Rocket Pharmaceuticals Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:9IP1 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
DTIL	54Neutral	$265.39M	-7.44	-58.09%	―	6353.01%	84.80%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ABEO	50Neutral	$140.30M	-2.05	-44.82%	―	9652.75%	-172.49%
LXEO	50Neutral	$251.19M	-2.67	-41.85%	―	―	64.51%
EDIT	45Neutral	$386.62M	-3.85	-130.43%	―	7.43%	74.00%
TNYA	41Neutral	$84.47M	-0.75	-115.21%	―	―	38.12%

* Healthcare Sector Average

Performance Comparison

DE:9IP1 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:9IP1	Rocket Pharma	2.15	-0.51	-19.05%
ABEO	Abeona Therapeutics Inc	2.30	-2.23	-49.23%
EDIT	Editas Medicine Inc.	2.38	-0.16	-6.30%
DTIL	Precision Biosciences	9.15	3.30	56.41%
TNYA	Tenaya Therapeutics, Inc.	0.37	-1.00	-72.92%
LXEO	Lexeo Therapeutics, Inc.	3.07	-5.92	-65.85%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Rocket Pharmaceuticals AI Stock Analysis